  |
Neonatal Drug Therapy Manual |
Remifentanil
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Indications:
- Premedication for non-urgent endotracheal intubation in neonates, when a fast onset of action and short duration narcotic is desired.
Administration:
- IV direct: over 1 - 2 minutes
Dosage:
- Rapid sequence intubation:
Side Effects:
- CNS: depression, dizziness, drowsiness, sedation
- CVS: bradycardia, hypotension
- Respiratory: depression, respiratory muscle stiffness
Reconstitution and Stability:
IV direct:
- Remifentanil 1 mg (1000 mcg) vial
- Add 1 mL of SWFI
- Take 0.1 mL (100 mcg) and add to 9.9 mL of 0.9%NaCl
- Final concentration: 10 mcg/mL
Compatibility:
- Solution Compatible: D5W, 0.9% NaCl, 0.45% NaCl, D5W/0.9% NaCl
- Y-site Compatible: calcium gluconate, dobutamine, dopamine, epinephrine, fentanyl, heparin, midazolam, morphine, potassium chloride
- Incompatible: amphotericin B, chlorpromazine, diazepam
References:
- Choong et al. Remifentanil for endotracheal intubation in neonates: a randomised controlled trial. Arch Dis Fetal Neonatal Ed 2010; 95: F80- F84
- Avino et al. Remifentanil versus Morphine-Midazolam Premedication on the Quality of Endotracheal Intubation in Neonates: A Noninferiority Randomised Trial. J. Pediat 2014; 164: 1032-7
- Welzing et al. Remifentanil for INSURE in preterm infants: a pilot study for evaluation of efficacy and safety aspects. Acta Ped 2009; 98: 1416-20
- Yerkes et al. Morphine versus remifentanil for intubating preterm neonates. Arch Dis Child Fetal Neonatal Ed 2007; 92: F293-294
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.
